Use of heteroaryl-3-oxo-propanenitrile derivatives in treating clinical wherein myelopoiesis suppression occurs
US5206258A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 12, 1991 |
| Grant date | Apr 27, 1993 |
| Priority date | — |
| Expiry date | Mar 12, 2011 |
Classification
- Technology area (CPC F)Mechanical Engineering; Lighting; Heating
- CPC primaryF04D29/601
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Heteroaryl-3-oxo-propanenitrile derivatives of formula (I) ##STR1## wherein X represents an oxygen atom or a --CH(R.sub.4)--, --O--CH(R.sub.4)--,--S(O).sub.n --, --S(O).sub.n --CH(R.sub.4)--, --CH(R.sub.4)--O--, --CH(R.sub.4)--S(O).sub.n -- or --CH(R.sub.4)--CH.sub.2 -- group wherein n is 0, 1 or 2; R.sub.1 represents C.sub.1 --C.sub.6 alkyl, pyridyl or unsubstituted or substituted phenyl; R.sub.2, R.sub.3 and R.sub.4 are as herein defined; and Q is hydrogen, carboxy, C.sub.2 -C.sub.7 - alkoxycarbonyl or a --CON(R.sub.a)R.sub.b group, R.sub.a and R.sub.b being as defined herein; and their pharmaceutically acceptable salts are useful in stimulating myelopoiesis in bone marrow suppressed mammals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.